pharmafileSeptember 20, 2018
Tag: Novartis , Amsterdam , health
It has been reported that the reason for the move was due to the high renovation costs of the current building on the Raapopseweg. Around 400 staff currently work at the Arnhem site and all will be affected by the move, with the expectation that they will transfer to the new base of operations.
The company said that the new destination was a "logical choice", given its close proximity to many clients and suppliers around the capital. The move is scheduled for mid-2019 and coincides with the controversial move of the European Medicines Agency to the city of Amsterdam, following the UK’s decision to leave the European Union which forced the agency to vacate its current base in London.
Jan van Dellen, Alderman for Economic Affairs and Sport in municipality of Arnhem, lamented the news, saying the departure of a company of Novartis’ stature is never good for the city, while Ron van Gent, Regional Director at Dutch employers' federation VNO-NCW, remarked: "We regret it very much. Novartis is an important company and it involves a large number of high-quality jobs in the Health cluster of Arnhem-Nijmegen."
Matt Fellows
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: